ClinicalTrials.gg
Not yet recruitingNCT07791420Updated Sep 1, 2026

Measurement of Acute Metabolite Changes Following Consumption of Microalgae Drinks

An interventional study of Bead-milled microalgae and Non-bead-milled microalgae in Protein Absorption and Amino Acid Availability and Metabolomics, sponsored by National University of Singapore. Not yet recruiting at 1 site in Singapore. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

Protein consumption is essential for various physiological processes, with microalgae and plant proteins gaining increasing attention due to their health benefits. To better understand how different protein types and processing methods impact health outcomes, this study aims to analyse the metabolite changes in response to different protein sources.

Read the detailed description

This study is a randomised crossover trial involving 16 participants. It comprises one screening visit and five test visits, during which participants will consume intervention drinks containing primarily (1) maltodextrin, (2) whey protein isolate, (3) soy protein isolate, (4) bead-milled microalgae, or (5) non-bead-milled microalgae in a randomised order. The study aims to investigate and compare acute postprandial metabolite responses following the consumption of bead-milled and non-bead-milled microalgae, as well as whey and soy protein isolates, in Singaporean adults.

02

Conditions studied

  • Protein Absorption and Amino Acid Availability
  • Metabolomics

Keywords

  • Protein absorption
  • Amino acid availability
  • Metabolomics
  • Processing
  • Microalgae
  • Acute
03

In context

Lead sponsor

National University of Singapore is the lead sponsor of 212 studies on the registry; 54 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • English-literate and able to give
  • Singaporean Chinese Adults aged 21 to 60 (inclusive)
  • of 18.5 to 23.0 kg/m\^2 (inclusive)
  • Healthy (Based on results from screening session)

Exclusion criteria

Exclusion Criteria:

  • Currently participating in another clinical study that involves altering the regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention
  • High blood pressure (≥ 140/90 mmHg)
  • Underlying health conditions that may affect metabolic functions
  • Consuming amino acid or protein supplements, or protein drinks, regularly (i.e., more than three times a week) for the past 3 months, and not willing to discontinue usage 3 months before and during the study duration
  • Weight change > 3 kg in the past 3 months
  • Weight \< 50 kg
  • Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)
  • Current smokers or have quit smoking for less than 5 years
  • Drinking > 2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)
  • If drinking ≤ 2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits
  • Not willing to stop consumption of caffeinated beverages 10 to 12 houFrs before and on the day of the test visits
  • Currently on a specialised diet (e.g., Halal, vegetarian, vegan, weight loss diet)
  • Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: seaweed or algae and their derived products, milk/dairy products (e.g., whey), starch/starch-derived products (e.g., rice, corn, wheat, potato), soy/soy-derived products, gluten, eggs, nuts, peanuts, fish and crustaceans
  • Disease or impairment of the kidney and/or liver*
  • Currently diagnosed with diabetes*, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency
  • Taking antibiotics 2 weeks prior to study participation
  • Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition
  • Poor peripheral venous access based on past experiences with blood drawing
  • Individuals with anemia and/or blood clotting disorders
  • Donated blood within the 12 weeks prior to study participation
  • Individuals with pacemaker or related electrical medical devices
  • Pregnant, lactating, or planning pregnancy in the next 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Bead-milled microalgae

    Consume a 400 mL drink containing 20 g protein equivalent of bead-milled microalgae

    Dietary Supplement: Bead-milled microalgae

  • Active comparator
    Non-bead-milled microalgae

    Consume a 400 mL drink containing 20 g protein equivalent of non-bead-milled microalgae

    Dietary Supplement: Non-bead-milled microalgae

  • Active comparator
    Whey protein isolate

    Consume a 400 mL drink containing 20 g protein equivalent of whey protein isolate

    Dietary Supplement: Whey protein isolate

  • Active comparator
    Soy Protein Isolate

    Consume a 400 mL drink containing 20 g protein equivalent of soy protein isolate

    Dietary Supplement: Soy protein isolate

  • Placebo comparator
    Maltodextrin

    Consume a 400 mL drink containing maltodextrin matched for the energy content of 20 g protein

    Dietary Supplement: Maltodextrin (Placebo)

Interventions

  • Dietary supplementBead-milled microalgae

    Consume a 400 mL drink containing 20 g protein equivalent of bead-milled microalgae

  • Dietary supplementNon-bead-milled microalgae

    Consume a 400 mL drink containing 20 g protein equivalent of non-bead-milled microalgae

  • Dietary supplementWhey protein isolate

    Consume a 400 mL drink containing 20 g protein equivalent of whey protein isolate

  • Dietary supplementSoy protein isolate

    Consume a 400 mL drink containing 20 g protein equivalent of soy protein isolate

  • Dietary supplementMaltodextrin (Placebo)

    Consume a 400 mL drink containing maltodextrin matched for the energy content of 20 g protein

06

What researchers measure

Primary outcomes

  1. Changes in metabolites found in plasma (plasma metabolomics)

    Targeted metabolomics profiling of plasma will be conducted using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS)

    Time frame: Baseline, 15, 30, 45, 60, 90, 120, 180, 240, 300 minutes

  2. Changes in metabolites found in urine (urinary metabolomics)

    Targeted metabolomics profiling of urine will be conducted liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS)

    Time frame: Baseline and 300 minutes

Secondary outcomes

  1. Appetite

    The Appetite Visual Analogue Scale (VAS) questionnaire will be administered, with participants rating five appetite-related outcomes, i.e. desire to eat, hunger, fullness, satisfaction, and prospective food consumption. Each response will be measured on a 100-mm visual analogue scale and scored from 0 to 100, with higher scores indicate a greater intensity of the outcomes being assessed, i.e. greater desire to eat, greater hunger, greater fullness, greater satisfaction, or a greater perceived amount of food that could be consumed.

    Time frame: Baseline, 60, 120, 180, 240, 300 minutes

07

Study locations

1 site
  • NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117550
    Singapore, Singapore
    • Marven Ng, B.Sc. · Contactngmarven@u.nus.edu · (+65) 8816 9977
    • Jung Eun Kim, Ph.D., R.D. · Principal investigator
08

References and documents

Publications

  • Williamson E, Monteyne AJ, Van der Heijden I, Abdelrahman DR, Murton AJ, Hankamer B, Stephens FB, Wall BT. Ingestion of 'whole cell' or 'split cell' Chlorella sp., Arthrospira sp., and milk protein show divergent postprandial plasma amino acid responses with similar postprandial blood glucose control in humans. Front Nutr. 2024 Nov 14;11:1487778. doi: 10.3389/fnut.2024.1487778. eCollection 2024. PubMed 39610880 ↗

Individual participant data

Plan to share: No — Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only to A/P Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Aug 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 28, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07791420
Responsible party
Jung Eun Kim (Associate Professor, National University of Singapore) — Principal investigator
First posted
Aug 28, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Marven Ng, B.Sc.
Contact
ngmarven@u.nus.edu
(+65) 8816 9977
Jung Eun Kim, Ph.D., R.D.
principal investigator · National University of Singapore, Department of Food Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion